Saturday, March 24, 2012: 9:45 a.m.-11 a.m.
Session Type: Poster Session
1.25 CE hours
Learning Objectives:
Discuss the outcomes of agents on clinical parameters
An In-Vitro Tubule Occlusion Model
B. SCHEMEHORN1, A. HAIDER1, and P. QUADROS2, 1Dental Product Testing, Therametric Technologies, Inc, Noblesville, IN, 2Fluidinova SA, Moreira da Maia, Portugal
Instant and Rapid Sensitivity Relief of a Stannous Containing Dentifrice
L. NI1, T. HE2, J. CHANG3, Y. HE3, and L. SUN3, 1Operative Dentistry & Endodontics,School of Stomatology, Fourth Military Medical University, Xi'an,Shaanxi Province, 710032, China, 2Oral Health Care, Procter & Gamble Company, Mason, OH, 3P&G, Beijing, China
Study To Asses The Anti-Plaque Efficacy Of Two Marketed Dentifrices
M. CRONIN1, T. HE2, H. EYNON2, M. MINER2, M.L. BARKER2, and M. SCHADT1, 1TKL Research, Inc, Ramsey, NJ, 2Oral Health Care, Procter & Gamble Company, Mason, OH
Superior Plaque Reduction Efficacy of a Stannous Fluoride Dentifrice
N. SHARMA1, J. QAQISH1, T. HE2, M.L. BARKER2, M. MINER2, H. EYNON2, and A. BIESBROCK2, 1BioSci Research America, Inc, Las Vegas, NV, 2The Procter & Gamble Company, Mason, OH
Overnight Anti-Plaque Benefits of Two Marketed Dentifrices using DPIA
I.M. TSAKNAKI1, A. ALHAFNE1, C. ERBE1, M. KLUKOWSKA2, M.L. BARKER3, H. TIMM4, C. JACOBS1, and H. WEHRBEIN1, 1Department of Orthodontics, University Medical Centre Mainz, Mainz, Germany, 2Oral Biology, Procter & Gamble Company, Mason, OH, 3Oral Care Clinical Research, Procter & Gamble Company, Mason, OH, 4Procter & Gamble, Kronberg, Germany
Clinical Anti-plaque Efficacy of a Novel 0.454% Stannous Fluoride Dentifrice
M. WYSS1, T. HE2, V. WIDMEYER2, M. MINER2, and M.L. BARKER2, 1Fidelis Clinical Research, Columbus, OH, 2The Procter & Gamble Company, Mason, OH
Plaque Viability Comparison Of 3 Commercial Dentifrices
T. TRIRATANA1, V. BARNES2, J. CHUNG2, R. RICHTER2, L. DU-THUMM2, and W. DEVIZIO2, 1Dept. of Oral Pathology, Mahidol University, Bangkok, Thailand, 2Colgate-Palmolive Company, Piscataway, NJ
Effect of Fluoride Varnish on Oral Symptoms During Chemotherapy
S. BANAVA1, M. HAKAK2, T. SAFAIE2, R. MALAYERI3, and M.J. KHARRAZIFARD4, 1Department of Restorative Dentistry, Islamic Azad University Dental Center, Tehran, Iran, 2Restorative Dentistry, Islamic Azad University Dental Center, Tehran, Iran, 3Center of Special Disease Care, Tehran, Iran, 4Research Center of Dental Faculty, Tehran University, Tehran, Iran
Anti-microbial effect of Selenium impregnated elastomeric ligatures in orthodontic patients
S. GROVER1, F. URIBE1, P. DIAZ2, W. NEACE1, A. YADEGARI3, and R. NANDA1, 1Orthodontics, University of Connecticut, Farmington, CT, 2Periodontics, University of Connecticut, Farmington, CT, 3Advanced education In general dentistry, University of Connecticut, Farmington, CT
Clinical Anti-plaque Efficacy of a 0.1% CPC Mouthrinse
R. CHENG1, A. WALANSKI1, R. GERLACH1, J. WITT1, and M. WYSS2, 1Health Care Research Center, Procter & Gamble Company, Mason, OH, 2Fidelis Clinical Research, Columbus, OH
Randomized Controlled Trial of 0.1% CPC Rinse on Gingival Bleeding
C. GARCIA-GODOY1, J. ROTHROCK1, V. MONZON1, R. CHENG2, J. WITT2, and R. GERLACH2, 1Nova Southeastern University, Ft. Lauderdale, FL, 2Health Care Research Center, Procter & Gamble Company, Mason, OH
Plaque Glycolysis Response to Cetylpyridinium Chloride Antimicrobial Mouthrinses
F. GARCIA-GODOY1, M. KLUKOWSKA2, Y. ZHANG1, L.K. JOHNSON1, L.A. DARNELL1, M.K. ANASTASIA2, R. CHENG2, V. WIDMEYER2, and D.J. WHITE2, 1College of Dentistry, University of Tennessee, Memphis, TN, 2Procter & Gamble Company, Mason, OH
![[ Visit AADR's Website ]](images/banner.jpg)